Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma
Figure 1
In vivo xenografts of human melanoma cancer cells treated with TekdeltaFc and LDM CTX. Relative tumor growth for each treatment group: Control, TekdeltaFc, low-dose metronomic cyclophosphamide (LDM CTX), and combination for two weeks. There were no statistically significant differences in tumor growth between treatment groups at any time points ().
